117 related articles for article (PubMed ID: 10900544)
1. Optimization of the formulation and characterization of the physicochemical properties of the novel platelet-activating factor receptor antagonist E5880.
Asai Y; Murahashi N; Iwamoto K
Drug Dev Ind Pharm; 2000 Aug; 26(8):873-8. PubMed ID: 10900544
[TBL] [Abstract][Full Text] [Related]
2. Formation of spherical micelles composed of the novel platelet activating factor receptor antagonist, E5880.
Asai Y
Pharm Dev Technol; 2005; 10(1):11-6. PubMed ID: 15776809
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the physicochemical properties of the micelles by the novel platelet activating factor receptor antagonist E5880.
Asai Y; Watanabe S
Eur J Pharm Biopharm; 2000 May; 49(3):219-23. PubMed ID: 10799812
[TBL] [Abstract][Full Text] [Related]
4. Formation of spherical micelles by the novel platelet activating factor receptor antagonist, E5880.
Nomura T; Asai Y; Murahashi N; Iwamoto K
Chem Pharm Bull (Tokyo); 2000 Jul; 48(7):947-50. PubMed ID: 10923821
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the physicochemical properties of micelles composed of the novel platelet activating factor receptor antagonist, E5880 in an aqueous environment.
Asai Y
Chem Phys Lipids; 2003 Jul; 124(2):103-9. PubMed ID: 12818736
[TBL] [Abstract][Full Text] [Related]
6. Formation of spherical micelles composed of the novel platelet activating factor receptor antagonist, E5880.
Asai Y
Pharmazie; 2005 Mar; 60(3):201-4. PubMed ID: 15801673
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunoassay for the novel platelet activating factor receptor antagonist E5880.
Suzuki H; Asano O; Tadano K; Horie T
J Pharm Sci; 1994 May; 83(5):657-61. PubMed ID: 8071816
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
9. A temperature study on critical micellization concentration of the novel platelet-activating factor receptor antagonist E5880 in water by electric conductivity measurements.
Asai Y; Nomura T; Murahashi N; Iwamoto K
Drug Dev Ind Pharm; 2000 May; 26(5):555-8. PubMed ID: 10789068
[TBL] [Abstract][Full Text] [Related]
10. Effect of a platelet-activating factor receptor antagonist, E5880, on cerebral vasospasm after aneurysmal subarachnoid hemorrhage--open clinical trial to investigate efficacy and safety.
Hirashima Y; Endo S; Nukui H; Kobayashi N; Takaku A
Neurol Med Chir (Tokyo); 2001 Apr; 41(4):165-75; discussion 175-6. PubMed ID: 11381675
[TBL] [Abstract][Full Text] [Related]
11. Prevention of cerebrovasospasm following subarachnoid hemorrhage in rabbits by the platelet-activating factor antagonist, E5880.
Hirashima Y; Endo S; Kato R; Takaku A
J Neurosurg; 1996 May; 84(5):826-30. PubMed ID: 8622157
[TBL] [Abstract][Full Text] [Related]
12. Platelet activating factor-induced apoptosis is inhibited by ectopic expression of the platelet activating factor G-protein coupled receptor.
Brewer C; Bonin F; Bullock P; Nault MC; Morin J; Imbeault S; Shen TY; Franks DJ; Bennett SA
J Neurochem; 2002 Sep; 82(6):1502-11. PubMed ID: 12354298
[TBL] [Abstract][Full Text] [Related]
13. Effect of a platelet-activating factor antagonist, E5880, on cerebrovasospasm following subarachnoid hemorrhage in a canine double-hemorrhage model.
Abe Y; Kasuya H; Suzuki S; Yamanishi Y; Hori T
Eur J Pharmacol; 2002 Nov; 455(2-3):127-33. PubMed ID: 12445578
[TBL] [Abstract][Full Text] [Related]
14. Effects of platelet-activating factor antagonist E5880 on intrahepatic and systemic metabolic responses to transient hepatic inflow occlusion and reperfusion in the rabbit.
Nakatani T; Sakamoto Y; Ando H; Kobayashi K
World J Surg; 1996 Oct; 20(8):1060-7; discussion 1067-8. PubMed ID: 8798365
[TBL] [Abstract][Full Text] [Related]
15. ABT-299, a potent antagonist of platelet activating factor.
Summers JB; Albert DH; Davidsen SK; Conway RG; Holms JH; Magoc TJ; Luo G; Tapang P; Rhein DA; Carter GW
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():475-7. PubMed ID: 7732895
[No Abstract] [Full Text] [Related]
16. Investigations on the lyophilisation of MPEG-hexPLA micelle based pharmaceutical formulations.
Di Tommaso C; Como C; Gurny R; Möller M
Eur J Pharm Sci; 2010 Apr; 40(1):38-47. PubMed ID: 20184955
[TBL] [Abstract][Full Text] [Related]
17. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis.
Biancone L; Cantaluppi V; Boccellino M; Bussolati B; Del Sorbo L; Conaldi PG; Albini A; Toniolo A; Camussi G
Am J Pathol; 1999 Nov; 155(5):1731-9. PubMed ID: 10550329
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation.
Bastos da Silva M; Delaunois A; Gustin P; Godeau JM; Lekeux P
Vet Res; 2000; 31(2):267-72. PubMed ID: 10779205
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the physicochemical properties of the micelles of platelet-activating factor (C18:0).
Asai Y; Nomura T; Murahashi N; Iwamoto K
Drug Dev Ind Pharm; 2000 Jun; 26(6):671-4. PubMed ID: 10826115
[TBL] [Abstract][Full Text] [Related]
20. Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs.
Fujita M; Seki T; Inada H; Shimizu K; Takahama A; Sano T
Bioorg Med Chem Lett; 2002 Feb; 12(3):341-4. PubMed ID: 11814792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
